Nicholas Investment Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nicholas Investment Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-38,520	Closed	-$3.81M	–	249
2024 Q3	$3.81M	Buy	+38,520	New	+$3.78M	0.35%	112
2024 Q1	–	Sell	-42,094	Closed	-$3.76M	–	226
2023 Q4	$3.76M	Buy	+42,094	New	+$3.13M	0.44%	85
2022 Q1	–	Sell	-4,407	Closed	-$493K	–	219
2021 Q4	$493K	Sell	4,407 -26,840	-86%	-$3.24M	0.03%	189
2021 Q3	$3.93M	Buy	+31,247	New	+$4.02M	0.29%	118

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Nicholas Investment Partners's XBI Position: Q4 2024 in Review

Nicholas Investment Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 38,520 shares — an estimated $3.81M sold.

Nicholas Investment Partners first reported a position in XBI in Q3 2021 and held it in 4 quarters. The position peaked at $3.93M in Q3 2021. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

Nicholas Investment Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
Nicholas Investment Partners sold 38,520 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $3.81M.
Nicholas Investment Partners first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and held it in 4 quarters.
Nicholas Investment Partners's State Street SPDR S&P Biotech ETF position peaked at $3.93M in Q3 2021.
738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Nicholas Investment Partners's 13F filing for Q4 2024, filed 14 Feb 2025.